Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 3 | — | — | — | 4 |
Ataxia | D001259 | — | R27.0 | 1 | 1 | — | — | — | 2 |
Cerebellar ataxia | D002524 | HP_0001251 | — | 1 | 1 | — | — | — | 2 |
Friedreich ataxia | D005621 | Orphanet_95 | G11.11 | — | 1 | — | — | — | 1 |
Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
Drug common name | LUVADAXISTAT |
INN | luvadaxistat |
Description | Luvadaxistat is an experimental drug that works as a D-amino acid oxidase inhibitor and is supposed to increase NMDA receptor functionality. It is developed to treat Friedrich ataxia and negative symptoms of schizophrenia.
|
Classification | Small molecule |
Drug class | enzyme inhibitors: D-amino acid oxidase (DAAO) inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=c1[nH]nc(CCc2ccc(C(F)(F)F)cc2)cc1O |
PDB | — |
CAS-ID | 1425511-32-5 |
RxCUI | — |
ChEMBL ID | CHEMBL2338801 |
ChEBI ID | — |
PubChem CID | 71270546 |
DrugBank | DB16067 |
UNII ID | 76IC00YRVR (ChemIDplus, GSRS) |